Pàgina inicial > Resultats de la cerca: Beissert, Stefan
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 3 registres trobats en 0.02 segons.
Articles, 3 registres trobats
Articles 3 registres trobats  
1.
10 p, 1.5 MB Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis : analysis of pooled data from the randomized trials SOLO 1 and SOLO 2 / Cork, M.J. (University of Sheffield Medical School) ; Eckert, L. (Sanofi) ; Simpson, E.L. (Oregon Health & Science University) ; Armstrong, A. (Keck School of Medicine at USC. University of Southern California) ; Barbarot, Sebastien (CHU Hôtel-Dieu) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Girolomoni, G. (University of Verona) ; de Bruin-Weller, Marjolein (University Medical Center Utrecht) ; Wollenberg, A. (Klinikum der Universität München) ; Kataoka, Y. (Osaka Habikino Medical Center) ; Remitz, A. (Helsinki University Central Hospital) ; Beissert, Stefan (Technische Universität Dresden) ; Mastey, V. (Regeneron Pharmaceuticals Inc.) ; Ardeleanu, Marius (Regeneron Pharmaceuticals Inc.) ; Chen, Z. (Regeneron Pharmaceuticals Inc.) ; Gadkari, A. (Regeneron Pharmaceuticals Inc.) ; Chao, J. (Regeneron Pharmaceuticals Inc.) ; Universitat Autònoma de Barcelona
Atopic dermatitis (AD) profoundly affects quality of life (QoL). Dupilumab significantly improves clinical outcomes, is well tolerated, and approved to treat inadequately controlled moderate-to-severe AD in adults; however, its effect on patient-reported outcomes (PROs) is not fully characterized. [...]
2020 - 10.1080/09546634.2019.1612836
Journal of Dermatological Treatment, Vol. 31 Núm. 6 (17 2020) , p. 606-614  
Registre complet - Creative Commons
2.
11 p, 1.5 MB Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis : interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up / Papp, Kim A (K Papp Clinical Research and Probity Medical Research) ; Lebwohl, M. G. (Icahn School of Medicine at Mount Sinai) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Ohtsuki, M. (Jichi Medical University) ; Beissert, Stefan (Department of Dermatology. University Hospital Carl Gustav Carus. TU Dresden) ; Zeng, J. (AbbVie Inc.) ; Rubant, S. (AbbVie Inc.) ; Sinvhal, R. (AbbVie Inc.) ; Zhao, Y. (AbbVie Inc.) ; Soliman, A.M. (AbbVie Inc.) ; Alperovich, G. (AbbVie Inc.) ; Leonardi, C. (Central Dermatology. Richmond Heights)
Background: Psoriasis is a chronic inflammatory skin disease requiring prolonged treatment. New biologic therapies require long-term evaluation to assess the durability of their efficacy and safety profiles over time. [...]
2021 - 10.1111/bjd.20595
British journal of dermatology, Vol. 185 Núm. 6 (december 2021) , p. 1135-1145  
Registre complet - Creative Commons
3.
13 p, 409.0 KB Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis / Worm, Margitta ; Simpson, Eric L. (Oregon Health & Science University, Portland) ; Thaçi, Diamant (University of Lübeck, Germany) ; Bissonnette, Robert (Innovaderm Research (Montreal, Canadà)) ; Lacour, Jean Philippe (Nice University Hospital (Niça, França)) ; Beissert, Stefan (Technische Universität Dresden, Germany) ; Kawashima, Makoto (Tokyo Women's Medical University, School of Medicine, Tokyo, Japan) ; Ferrándiz, Carlos (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Smith, Catherine H. (King's College London) ; Beck, Lisa (University of Rochester Medical Center, New York) ; Chan, Kuo-Chen (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Chen, Zhen (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Akinlade, Bolanle (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Hultsch, Thomas (Sanofi Genzyme, Cambridge, Massachusetts) ; Staudinger, Heribert (Sanofi, Bridgewater, New Jersey) ; Gadkari, Abhijit (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Eckert, Laurent (Sanofi, Chilly-Mazarin, France) ; Davis, John D. (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Rajadhyaksha, Manoj (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Graham, Neil M. H. (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Pirozzi, Gianluca (Sanofi, Bridgewater, New Jersey) ; Stahl, Neil (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Yancopoulos, George D. (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Ardeleanu, Marius (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Universitat Autònoma de Barcelona. Departament de Medicina
The dupilumab regimen of 300 mg every 2 weeks is approved for uncontrolled, moderate to severe atopic dermatitis (AD). To assess the efficacy and safety of different dupilumab regimens in maintaining response after 16 weeks of initial treatment. [...]
2019 - 10.1001/jamadermatol.2019.3617
JAMA Dermatology, Vol. 156 (december 2019) , p. 131-143  
Registre complet - Creative Commons

Vegeu també: autors amb noms similars
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem